Redsense Medical (REDS) Q3 2025 earnings summary

Executive summary

• Net sales grew 38% in Q3 2025 year-over-year, with the US accounting for 99% of sales.

• Operating loss (EBIT) improved to KSEK -428 in Q3 2025 from KSEK -3,272 in Q3 2024.

• Gross margin for Q3 was 54%, slightly down from 58% in the prior year.

• Cash and cash equivalents stood at KSEK 12,239 at quarter-end.

• Significant events included a preemptive order ahead of tariff increases and CE marking of the Clamp, with launches in the UK, Canada, and Germany.

Financial highlights

• Q3 2025 net sales: KSEK 6,935 (Q3 2024: KSEK 5,030), a 38% increase.

• Q3 2025 operating loss (EBIT): KSEK -428 (Q3 2024: KSEK -3,272).

• Q3 2025 result after tax: KSEK -345 (Q3 2024: KSEK -3,271).

• Earnings per share in Q3: SEK -0.21 (Q3 2024: SEK -1.99).

• Gross profit in Q3: KSEK 3,778 (Q3 2024: KSEK 2,921).

Outlook and guidance

• Stable demand expected, but geopolitical and trade uncertainties may impact new market traction.

• Company is better positioned than last year due to operational improvements and stronger fundamentals.

• Ongoing focus on innovation, efficiency, and patient safety.